Gritstone bio lays off 40% of staff following Covid vaccine trial delay
Vaccine biotech Gritstone bio is cutting its headcount by about 40% after it announced earlier this month that the Phase IIb …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
